• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症患者支持性护理的经济负担。

The economic burden of supportive care of cancer patients.

作者信息

Elting Linda S, Shih Ya-Chen Tina

机构信息

Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

出版信息

Support Care Cancer. 2004 Apr;12(4):219-26. doi: 10.1007/s00520-003-0513-1. Epub 2004 Feb 7.

DOI:10.1007/s00520-003-0513-1
PMID:14767748
Abstract

GOALS OF WORK

Economic and regulatory healthcare policy is limited by the lack of population-based information on the cost of supportive care of cancer patients. The goal of this study was to estimate these costs and to explore the impact of these costs on policy decisions.

PATIENTS AND METHODS

We identified estimates of the cost of outpatient and inpatient supportive care from published reports in the literature. The range of these costs (from lowest to highest) is described for each supportive care condition. These estimates were supplemented by computing the cost of all hospitalizations for these conditions in Texas between June 2000 and December 2001. Medicare payments were used to estimate average reimbursement. Costs (not charges) were standardized to 2002 US dollars using the consumer price index for medical care and Medicare's cost-to-charge ratio for Texas.

MAIN RESULTS

Inpatient care for most conditions exceeded 7,000 US dollars per episode. Our population-based estimates of the cost of care were similar to literature-based estimates, except in the case where conditions could be managed in the outpatient setting. Average Medicare payments were often far lower than the estimated cost of care. For example, the estimated cost of hospitalization for management of diarrhea was 6,616 US dollars while the average Medicare payment was only 2,809 US dollars.

CONCLUSIONS

Many supportive care interventions are quite expensive. In an environment focused on cost containment, a risk-based approach to expensive supportive care treatments is essential. Further study of the cost effectiveness of supportive care management strategies is indicated.

摘要

工作目标

由于缺乏基于人群的癌症患者支持性护理成本信息,医疗保健的经济和监管政策受到限制。本研究的目的是估算这些成本,并探讨这些成本对政策决策的影响。

患者与方法

我们从文献中已发表的报告中确定了门诊和住院支持性护理成本的估算值。针对每种支持性护理情况描述了这些成本的范围(从最低到最高)。通过计算2000年6月至2001年12月期间德克萨斯州这些情况的所有住院费用对这些估算值进行了补充。使用医疗保险支付来估算平均报销额。使用医疗保健消费者价格指数和德克萨斯州医疗保险的成本收费比,将成本(而非收费)标准化为2002年美元。

主要结果

大多数情况下,每次住院护理费用超过7000美元。我们基于人群的护理成本估算值与基于文献的估算值相似,但在可以在门诊环境中管理的情况下除外。医疗保险的平均支付额往往远低于估计的护理成本。例如,腹泻管理的住院估计成本为6616美元,而医疗保险的平均支付额仅为2809美元。

结论

许多支持性护理干预措施相当昂贵。在注重成本控制的环境中,对昂贵的支持性护理治疗采取基于风险的方法至关重要。表明需要进一步研究支持性护理管理策略的成本效益。

相似文献

1
The economic burden of supportive care of cancer patients.癌症患者支持性护理的经济负担。
Support Care Cancer. 2004 Apr;12(4):219-26. doi: 10.1007/s00520-003-0513-1. Epub 2004 Feb 7.
2
Direct medical cost of managing deep vein thrombosis according to the occurrence of complications.根据并发症发生情况管理深静脉血栓形成的直接医疗费用。
Pharmacoeconomics. 2002;20(9):603-15. doi: 10.2165/00019053-200220090-00004.
3
Cost of managing an episode of relapse in multiple sclerosis in the United States.美国多发性硬化症复发一次的管理成本。
BMC Health Serv Res. 2003 Sep 2;3(1):17. doi: 10.1186/1472-6963-3-17.
4
Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment.骨折复位影响医疗保险经济学(FRAME):骨质疏松症诊断与治疗增加的影响
Osteoporos Int. 2005 Dec;16(12):1545-57. doi: 10.1007/s00198-005-1869-5. Epub 2005 Jun 8.
5
Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.估算美国社区获得性肺炎患者住院时间缩短半天所产生的经济影响。
Curr Med Res Opin. 2009 Sep;25(9):2151-7. doi: 10.1185/03007990903102743.
6
Costs associated with outpatient, emergency room and inpatient care for migraine in the USA.美国偏头痛患者的门诊、急诊和住院治疗费用。
Cephalalgia. 2011 Nov;31(15):1570-5. doi: 10.1177/0333102411425960. Epub 2011 Oct 19.
7
Nonoperative care to manage sacroiliac joint disruption and degenerative sacroiliitis: high costs and medical resource utilization in the United States Medicare population.非手术治疗管理骶髂关节紊乱和退行性骶髂关节炎:美国医疗保险人群的高成本和医疗资源利用。
J Neurosurg Spine. 2014 Apr;20(4):354-63. doi: 10.3171/2014.1.SPINE13188. Epub 2014 Feb 14.
8
Economic burden of schizophrenia: empirical analyses from a survey in Thailand.精神分裂症的经济负担:来自泰国一项调查的实证分析。
J Ment Health Policy Econ. 2012 Mar;15(1):25-32.
9
Contribution of preventable acute care spending to total spending for high-cost Medicare patients.可预防的急性护理支出对高成本 Medicare 患者总支出的贡献。
JAMA. 2013 Jun 26;309(24):2572-8. doi: 10.1001/jama.2013.7103.
10
Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.评估化疗引起的发热性中性粒细胞减少症的总成本:一项针对社区肿瘤癌症患者的试点研究结果。
Oncologist. 2007 Apr;12(4):478-83. doi: 10.1634/theoncologist.12-4-478.

引用本文的文献

1
Resource utilization and cost of diarrhea-related hospitalizations among cancer patients in Jordan.约旦癌症患者腹泻相关住院治疗的资源利用情况及费用
Support Care Cancer. 2025 May 28;33(6):508. doi: 10.1007/s00520-025-09581-9.
2
Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study.瑞立柯仑联合纳米白蛋白紫杉醇治疗复发性铂耐药卵巢癌:一项成本效益研究。
J Gynecol Oncol. 2025 Jul;36(4):e63. doi: 10.3802/jgo.2025.36.e63. Epub 2025 Feb 20.
3
Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis.

本文引用的文献

1
Current trends in the use of pharmacoeconomics and outcomes research in europe.欧洲药物经济学与结果研究的当前应用趋势
Value Health. 1999 Sep-Oct;2(5):323-32. doi: 10.1046/j.1524-4733.1999.25003.x.
2
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.促红细胞生成素在癌症患者中的应用:对美国及其他国家肿瘤学家临床实践模式的评估
Am J Med. 2004 Jan 1;116(1):28-34. doi: 10.1016/j.amjmed.2003.06.004.
3
A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain.
在激素受体阳性晚期乳腺癌患者中,将卡哌西他滨添加到氟维司群治疗中:一项成本效益分析。
Front Pharmacol. 2025 Jan 15;15:1495082. doi: 10.3389/fphar.2024.1495082. eCollection 2024.
4
Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer.二线奈拉替尼联合卡培他滨与拉帕替尼联合卡培他滨用于HER2阳性转移性乳腺癌的经济学评估
Front Oncol. 2023 Aug 9;13:1221969. doi: 10.3389/fonc.2023.1221969. eCollection 2023.
5
Cancer survival stories: Perception, creation, and potential use case.癌症生存故事:感知、创造和潜在应用案例。
Health Expect. 2023 Aug;26(4):1551-1561. doi: 10.1111/hex.13760. Epub 2023 May 3.
6
Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.在治疗 HR+/HER2-晚期或转移性乳腺癌的绝经后妇女中,加用瑞博西利联合氟维司群是否具有成本效益?一项基于美国支付者视角的成本效用分析。
J Manag Care Spec Pharm. 2022 Nov;28(11):1282-1291. doi: 10.18553/jmcp.2022.28.11.1282.
7
Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.内分泌治疗耐药或三阴性转移性乳腺癌女性的药物治疗选择的成本效益分析。
J Clin Oncol. 2023 Jan 1;41(1):32-42. doi: 10.1200/JCO.21.02473. Epub 2022 Sep 2.
8
What Oncologists Must Account for: The Financial Burden of Cancer-Associated Symptom Relief.肿瘤学家必须考虑的因素:癌症相关症状缓解的经济负担。
JCO Oncol Pract. 2022 Feb;18(2):106-108. doi: 10.1200/OP.21.00727. Epub 2021 Nov 30.
9
Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.达可替尼与吉非替尼用于美国和中国表皮生长因子受体(EGFR)突变阳性非小细胞肺癌患者一线治疗的成本效益分析
Ann Transl Med. 2021 May;9(9):760. doi: 10.21037/atm-20-6992.
10
Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective.阿贝西利联合氟维司群用于HR+/HER2-晚期或转移性乳腺癌二线治疗的成本效益分析:美国医保支付方视角
Front Med (Lausanne). 2021 Jun 2;8:658747. doi: 10.3389/fmed.2021.658747. eCollection 2021.
一项针对有和没有爆发性疼痛病史的癌症患者报告的与疼痛相关的住院、急诊就诊和门诊就诊情况的调查。
J Pain. 2002 Feb;3(1):38-44. doi: 10.1054/jpai.2002.27136.
4
Quality of life and economic considerations in the management of prostate cancer.前列腺癌管理中的生活质量与经济考量
Pharmacoeconomics. 2003;21(8):527-41. doi: 10.2165/00019053-200321080-00001.
5
Complications and costs after high-risk surgery: where should we focus quality improvement initiatives?高风险手术后的并发症与成本:我们应将质量改进措施聚焦于何处?
J Am Coll Surg. 2003 May;196(5):671-8. doi: 10.1016/S1072-7515(03)00122-4.
6
Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas.急性白血病和淋巴瘤患儿发热性中性粒细胞减少发作的资源利用与成本
Support Care Cancer. 2003 Jun;11(6):356-61. doi: 10.1007/s00520-002-0429-1. Epub 2003 Apr 26.
7
Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors.淋巴瘤或实体瘤患者化疗引起的血小板减少症的成本。
Cancer. 2003 Mar 15;97(6):1541-50. doi: 10.1002/cncr.11195.
8
Management patterns and health care use after intracerebral hemorrhage. a cost-of-illness study from a societal perspective in Germany.脑出血后的管理模式与医疗保健利用。一项从德国社会视角进行的疾病成本研究。
Cerebrovasc Dis. 2003;15(1-2):29-36. doi: 10.1159/000067119.
9
Resource utilization for acute lower gastrointestinal hemorrhage: the Ontario GI bleed study.急性下消化道出血的资源利用:安大略省胃肠道出血研究
Can J Gastroenterol. 2002 Oct;16(10):677-82. doi: 10.1155/2002/156592.
10
Direct medical cost of managing deep vein thrombosis according to the occurrence of complications.根据并发症发生情况管理深静脉血栓形成的直接医疗费用。
Pharmacoeconomics. 2002;20(9):603-15. doi: 10.2165/00019053-200220090-00004.